- Atezolizumab in the first line of treatment for non-squamous metastatic non-small cell lung cancer2019 | Second Faculty of Medicine
- First-line pembrolizumab for metastatic non-small-cell lung cancer2020 | First Faculty of Medicine
- Erlotinib in the first line treatment of the metastatic non-small cell lung cancer2018 | Third Faculty of Medicine
- Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study2023 | Publication without faculty affiliation
- Treatment of advanced and metastatic non small cell lung cancer, second line therapy2000 | Faculty of Medicine in Pilsen
- Current therapeutic options for advanced/metastatic non-small cell lung cancer2011 | Publication without faculty affiliation
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen
- Immunotherapy and radiotherapy in locally advanced (metastatic) non small cell lung cancer2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Strategy of treatment of metastatic non-small-cell lung cancer - squamous cell carcinoma2016 | First Faculty of Medicine
- Gemcitabine in locally advanced and metastatic non-small cell lung cancer: The Central European phase II study1998 | Third Faculty of Medicine
- Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectini2020 | Publication without faculty affiliation
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial2019 | Second Faculty of Medicine
- A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer2008 | Third Faculty of Medicine
- Randomized phase III trial comparing bexarotene (L106949)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I2008 | Third Faculty of Medicine
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Research Report University Hospital of the clinical trial 1200.55Publication without faculty affiliation
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Tagrisso TM (Osimertinib, AZD929I)2016 | Faculty of Medicine in Pilsen
- Immunotherapy in the first line treatment of non-small cell lung cancer2021 | Publication without faculty affiliation
- What brings modern therapy to advanced non small cell lung cancer2017 | Faculty of Medicine in Pilsen
- Targeted treatment and immunotherapy of advanced non-small cell lung cancer2022 | First Faculty of Medicine
- Atezolizumab2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Pembrolizumab in the treatment of non-small-cell lung cancer2016 | Publication without faculty affiliation
- Therapy of metastatic non-squamous lung cancer with bevacizumab plus pemetrexed2016 | Faculty of Medicine in Pilsen
- Atypical response to anti-PD-1 therapy followed by long-term survival in non-small cell lung cancer - case reports2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Immunotherapy in the first line treatment of non-small cell lung cancer2020 | Faculty of Medicine in Pilsen
- Monotherapy with pembrolizumab in the first-line treatment of non-small cell lung cancer with a high expression of PD-L1 >= 50 %2020 | Faculty of Medicine in Pilsen
- Immunotherapy in squamous NSCLC - nivolumab clinical data, our experiences with nivolumab treatment2018 | Faculty of Medicine in Pilsen
- Efficiency and safety of pemetrexed and cisplatin therapy in the adenocarcinoma and large cell cancer types of advanced non-small cell lung cancer (NSCLC)2012 | Publication without faculty affiliation
- Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance2019 | Faculty of Pharmacy in Hradec Králové